Abingdon Health

Abingdon Health is a UK in-vitro diagnostics company headquartered in York. Its activities include rapid testing technologies, lateral-flow assay development, and contract development and manufacturing for diagnostic products. The company supports customers across stages such as assay design, reagent and process development, technology transfer, scale-up, and manufacturing, while also developing or commercialising branded and partner-led testing products. Its work has covered healthcare, life-science, and consumer-health applications. Abingdon Health was involved in the development of the AbC-19 antibody test during the COVID-19 pandemic. The company is listed on the London Stock Exchange’s AIM market under the ticker ABDX. In addition to individual test products, its market positioning includes providing lateral-flow platforms and manufacturing capabilities to diagnostic companies. The current commercial status and geographic availability of particular products should be checked against the company’s latest announcements and product materials.

Abingdon Health is a UK in-vitro diagnostics company whose capabilities centre on rapid testing and lateral-flow technology. It operates both as a contract development and manufacturing provider and as a developer or commercialisation partner for branded and collaborative diagnostic products. Its activities can cover assay design, development and verification, process scale-up, manufacturing, and product support. This gives the company a role extending beyond that of a standalone test brand to include diagnostic technology services and manufacturing. During the COVID-19 pandemic, Abingdon Health was involved in the AbC-19 antibody test project, which brought increased attention to the company in the UK rapid-testing and antibody-testing sectors. The company has continued to position its business around in-vitro diagnostic development, lateral-flow platforms, and manufacturing services. Abingdon Health is listed on the AIM market of the London Stock Exchange under the ticker ABDX. Because products and collaborative projects may change with regulatory status, commercial arrangements, and market demand, the current status of individual products should be confirmed through recent company materials.

• AbC-19

  AbC-19 was a COVID-19 antibody rapid-test project involving Abingdon Health and using lateral-flow technology to detect antibodies associated with prior infection. It was one of the company’s most visible testing projects during the pandemic; its current availability and commercial status should be confirmed through up-to-date regulatory and company information.

1. 1Abingdon Health official websiteabingdonhealth.com
2. 2Abingdon Health investor relationsabingdonhealth.com
3. 3Abingdon Health PLC: Abingdon Health Plc signs distribution agreement with BioSure UKfinanznachrichten.de